A clinical study of 11 dogs with advanced malignant melanoma demonstrated the efficacy, safety, and tolerability profile of cANK-101, a canine interleukin-12 anchored immunotherapy.
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
Introducing medical devices — commonly made of materials such as titanium, silicone, or collagen — into our bodies can elicit a host of different immune responses. While some responses can harm our bodies, others can help heal them. Researchers have not fully grasped the rhyme or reason behind the body’s reactions, but a new study fills in a critical piece of the puzzle.
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer. The results were simultaneously reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology.
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center.
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
While COVID-19 breakthrough infections—a SARS-CoV-2 infection that occurs after receiving COVID-19 vaccines—can occur, for healthy individuals with vaccine-induced immunity, these breakthrough infections do not often cause severe disease.
Researchers at Kyushu University have discovered that turning brain immune cells into neurons successfully restores brain function after stroke-like injury in mice. These findings, published on October 10 in PNAS, suggest that replenishing neurons from immune cells could be a promising avenue for treating stroke in humans.
SEATTLE – OCTOBER 17, 2023 – Fred Hutchinson Cancer Center has announced the recipients of the 2023 Dr. Eddie Méndez Scholar Award, which recognizes early-career underrepresented minority scientists and scientists with disabilities.
A brief filed on behalf of 111 public health and health law and policy Deans and Scholars, the American Public Health Association, the Robert Wood Johnson Foundation, Trust for America’s Health, and ChangeLab Solutions highlights new findings on the preventive health gains at stake in Braidwood Management v Becerra.
Dendritic cells are key orchestrators of the immune response, but most vaccination strategies don’t effectively target them. NIBIB-funded researchers have developed biodegradable nanoparticles that are designed to deliver mRNA cargo to dendritic cells in the spleen.
A guide to vaccines that adults - especially older adults and those with underlying health issues - should get to avoid serious illness this fall and winter, and beyond.
The Association for Molecular Pathology has published best practice recommendations for validating and reporting clinical circulating tumor DNA (ctDNA) or liquid biopsy assays and their related scientific publications.
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the effectiveness and safety of primary single-agent and combination therapies in treating adult patients with relapsed immune thrombocytopenia (ITP).
UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.
Immune cells play a key role during pregnancy, adjusting immune system response in a way that enables the fetus to develop while also protecting the parent and fetus from outside assaults like viruses.
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found. In mouse models of melanoma, bladder cancer, leukemia and colon cancer, the drug slows the growth of tumors, extends lifespan and boosts the efficacy of immunotherapy.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new role for a protein called extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that can trigger cells to self-destruct.
New analysis of the remains of victims of the 1918 influenza pandemic, which killed an estimated 50 million people worldwide, contradicts the widespread belief the flu disproportionately impacted healthy young adults.
Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells). When used in patients with advanced non-small cell lung cancer undergoing immunotherapy, they may identify patients who could benefit from treatment with additional drugs, according to a phase 2 clinical trial in the U.S. and Canada. The trial is led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer and the Canadian Cancer trials Group (CCTG).
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
A person’s immune response to variants of SARS-CoV-2, the virus that causes COVID-19, depends on their previous exposure – and differences in the focus of immune responses will help scientists understand how to optimise vaccines in the future to provide broad protection.
Every year, over 15,500 Australians are diagnosed with bowel cancer, and it is the second leading cause of cancer deaths in the country. Over 1,700 (one in ten) of those diagnosed are young Australians aged under 50, and this incidence is increasing.
In 2019, St. Jude lentiviral gene therapy restored the immune system in multiple infants of X-linked severe combined immunodeficiency disorder (SCID-X1) or “bubble boy disease” at the DNA level. These children can now produce functional immune systems.
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
ICD-10 codes are not the kind of thing that Jonathan Santoro, MD, learned about in medical school, or in his yearslong training to become a pediatric neurologist and neuroimmunologist. In fact, for most of his career he never spent any time thinking about them.
Using laboratory-grown cells from humans and genetically engineered mice, scientists at Johns Hopkins Medicine say they have evidence that modifying a specific protein in immune white blood cells known as CD8+ T cells can make the cells more robust, potentially opening the door for better use of people’s own immune system T cells to fight cancer.
Memory B cells depend on autophagy for their survival, but the protein Rubicon is thought to hinder this process. Researchers from Osaka University have discovered a shorter isoform of Rubicon called RUBCN100, which enhances autophagy in B cells.
Cal State Fullerton antibiotic-resistance researcher María Soledad Ramírez and her students have discovered a promising new therapeutic to treat Acinetobacter baumannii, a superbug commonly found in hospitals and resistant to many antibiotics.
Collaborative webinars to focus on key scientific trends and findings related to gut microbiome and nutrition, and the interaction of diet, stress and immune function.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
The notion that some level of microbial exposure might reduce our risk of developing allergies has arisen over the last few decades and has been termed the hygiene hypothesis.
Researchers at Stanford University School of Medicine, Yale University School of Medicine, and the Hospital for Special Surgery Research Institute have uncovered new details about how the immune system prevents the production of antibodies that can recognize and damage the body’s own, healthy tissues. The study, to be published September 29 in the Journal of Experimental Medicine (JEM), also reveals how this process is impaired in autoimmune disorders such as systemic sclerosis and systemic lupus erythematosus and suggests potential new strategies to treat these diseases.
The organisms that cause visceral leishmaniasis, a potentially deadly version of the parasitic disease that most often affects the skin, appear to have a secret weapon, new research suggests: They can infect non-immune cells and persist in those uncommon environments.
Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.
Not for public release
This news release is embargoed until 28-Sep-2023 11:00 AM EDT
Released to reporters: 28-Sep-2023 10:45 AM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 28-Sep-2023 11:00 AM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Tuberculosis is old—ancient even. The infectious bacterial disease that plagued Old Testament Israelites and took down pharaohs was eventually stunted by vaccinations, antibiotics, and public health measures like isolation, but it hasn’t been cured yet. More than a million people around the world still die from TB every year.
A single-dose therapy has been developed that is highly effective against lyssavirus infection (rabies), one of the deadliest known viral infections of humans.
A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.